• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cue Biopharma Inc (NQ: CUE )

    1.350 +0.050 (+3.85%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 331,762
    Open 1.300
    Bid (Size) 1.270 (216)
    Ask (Size) 1.370 (7)
    Prev. Close 1.300
    Today's Range 1.260 - 1.370
    52wk Range 1.260 - 4.890
    Shares Outstanding 44,959,548
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
    From Cue Biopharma, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -51.44%
    -51.44%
    1 Month
    -29.32%
    -29.32%
    3 Month
    -28.95%
    -28.95%
    6 Month
    -54.85%
    -54.85%
    1 Year
    -65.38%
    -65.38%

    More News

    Read More
    Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
    Via InvestorPlace
    Forecasting The Future: 4 Analyst Projections For Cue Biopharma
    Via Benzinga
    Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain
    Via Investor Brand Network
    CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Cue Biopharma to Host Business Update Call and Webcast
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023
    Via InvestorPlace
    Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma to Host Business Update Call and Webcast
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
    From Cue Biopharma, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.